Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Cuts Loss 84 Percent on Slight Quarterly Revenue Gain

NEW YORK (GenomeWeb News) - Accelrys yesterday reported a 2 percent increase in fiscal fourth-quarter revenues as R&D spending fell 22 percent and the company cut its quarterly loss by 84 percent.
 
Total receipts for the three months ended March 31, 2007, increased to $19.9 million from $19.4 million year over year.
 
Accelrys said growth in its SciTegic Pipeline Pilot product line was offset by reduced sales of legacy products that were “deemphasized" due to product line restructuring.
 
R&D spending decreased to $4.2 million from $5.3 million year over year.
 
Net loss dropped to $1.1 million from $6.4 million in the year-ago period. Accelrys said cost controls it implemented over the past two years helped it reduce its loss for the quarter.
 
Accelrys said it had around $70.8 million in cash, cash equivalents and marketable securities as of March 31.

Filed under

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.